One study examining the effects of DKN-01 treatment or DKK-1 overexpression in endometrioid ovarian cancer (EOC) releveled that overexpression of DKK-1 caused a decrease in immune activity while treatment with DKN-01 did not phenotypically affect EOC cells in vitro, indicating that DKN-01 functions by modulating anti-tumor immunity (61). The gene discussed is DKK1; the disease is ovarian endometrioid adenocarcinoma.